Contact Us: 1-888-667-3325 /

Subscriber Content Preview | Request a free trialSearch  


Splitting Danaher in two might not be enough

Third Point's Dan Loeb takes a large stake. Is he along for the ride or will he push for more buybacks and divestitures? Continue reading

Delaware's drive to reduce M&A suits bears some fruit

Time will tell whether a reduction in class actions belies a shift to other state courts. Continue reading

The Most Admired Corporate Dealmakers

Ten companies are singled out for their M&A prowess in what's expected to be the biggest year for deals since 2007. Continue reading

Cardio microcaps need plenty of heart to face PIPE financing climate

Some issuers are desperate for cash as many investors step back in the final quarter. Continue reading

Pfizer's bid for Allergan may be too good to turn down

With Pfizer's need for tax savings and pipeline products, an offer is expected to hand Allergan shareholders a 30% premium. Continue reading

Pfizer, Allergan merger would reignite debate on corporate tax inversions

Pfizer is trying to do with Allergan, what it failed to do with AstraZeneca last year -- cut its tax bill. Continue reading

Bill Ackman gets a taste of his own medicine at Valeant

The activist investor boosts his stake to 6.3% in the embattled drug producer, whose CEO disputes a short seller's allegations that the company was involved in questionable practices. Continue reading

Private equity smells the growth in the cannabis industry

Growth of legal marijuana industry begins to attract professional capital as the cannabis business eyes new markets. Continue reading

El Paso Children's Hospital reaches deal with landlord

The medical facility operator intends to file a reorganization plan outlining the terms of the deal, despite interest from a suitor. Continue reading

Exclusive: Verisk Analytics hires Morgan Stanley to sell healthcare business

The unit, which posts Ebitda of around $90 million, could be worth $900 million to $1.1 billion. Continue reading

As university spinouts proliferate, so does worry about failures

Lawyers expect more of these startups to file for bankruptcy because many lack commercial viability or financing. Continue reading

FTC chief defends unique antitrust powers

GOP efforts to standardize merger challenge framework gain steam. Continue reading

Meet the journalists

William Blair's Dan Shedivy sits down to talk M&A in the healthcare services sector

Middle Market healthcare deals stayed strong in 2014 but were relative ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

Our senior journalists host the industry's leading forecasting event, where influential members of the deal community discuss the outlook for dealmaking.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!